Pages that link to "Q51804140"
Jump to navigation
Jump to search
The following pages link to Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. (Q51804140):
Displaying 22 items.
- Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. (Q35113402) (← links)
- Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases (Q35920259) (← links)
- Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation (Q36299062) (← links)
- Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases (Q36615997) (← links)
- Role of surgery in colorectal liver metastases: too early or too late? (Q37774980) (← links)
- Surgery combined with oncological treatments in liver metastases from colorectal cancer (Q37863930) (← links)
- Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis (Q38024277) (← links)
- Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients (Q38187905) (← links)
- Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases. (Q38661967) (← links)
- A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination (Q39567268) (← links)
- Emergency open incarcerated hernia repair with a biological mesh in a patient with colorectal liver metastasis receiving chemotherapy and bevacizumab uncomplicated wound healing. (Q41525440) (← links)
- Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. (Q43967231) (← links)
- Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab (Q44895824) (← links)
- The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. (Q45047438) (← links)
- Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases (Q45094736) (← links)
- Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment (Q46183954) (← links)
- Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. (Q47784587) (← links)
- Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. (Q51193100) (← links)
- Hepatectomy for Colorectal Cancer Liver Metastases in the Era of Modern Preoperative Chemotherapy: Evaluation of Postoperative Complications. (Q53020665) (← links)
- The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. (Q53026533) (← links)
- Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma (Q85411312) (← links)
- Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases (Q92727057) (← links)